Evaluating the Cardiorenal Benefits of Dapagliflozin and Valsartan in Individuals with Type 2 Diabetes and Hypertension: A Retrospective Cohort Analysis - Report - MDSpire
Advertisement
Evaluating the Cardiorenal Benefits of Dapagliflozin and Valsartan in Individuals with Type 2 Diabetes and Hypertension: A Retrospective Cohort Analysis
Cardiorenal Benefits of Dapagliflozin Plus Valsartan in T2DM with Hypertension
Overview
This retrospective cohort study demonstrated that combining dapagliflozin with valsartan in patients with type 2 diabetes mellitus and hypertension resulted in superior improvements in blood pressure, glycemic control, inflammatory and cardiac biomarkers, renal function, and fibrosis markers compared to valsartan monotherapy over 24 weeks.
Background
Type 2 diabetes mellitus (T2DM) and hypertension frequently coexist and synergistically increase the risk of cardiovascular and renal complications. Conventional therapies often inadequately address the intertwined pathophysiological mechanisms such as inflammation and fibrosis that contribute to cardiorenal deterioration. Sodium-glucose cotransporter 2 (SGLT2) inhibitors like dapagliflozin and angiotensin receptor blockers (ARBs) such as valsartan have complementary mechanisms that may provide enhanced cardiorenal protection. This study aimed to evaluate the efficacy of dapagliflozin combined with valsartan versus valsartan alone in this high-risk population.
Data Highlights
Parameter
Combination Group (Valsartan + Dapagliflozin)
Monotherapy Group (Valsartan only)
Systolic BP (mmHg)
134.86 ± 6.37
139.68 ± 6.82
Diastolic BP (mmHg)
83.12 ± 4.58
86.29 ± 4.79
Fasting Plasma Glucose (mmol/L)
6.79 ± 1.02
7.58 ± 1.10
2-hour Postprandial Glucose (mmol/L)
9.71 ± 1.68
11.24 ± 1.84
Left Ventricular Ejection Fraction (%)
60.12 ± 4.68
56.75 ± 4.96
eGFR (Renal function)
Improved (P < 0.05)
Less improvement
NT-proBNP (Cardiac biomarker)
Significantly reduced (P < 0.05)
Less reduction
Fibrosis markers (PIIINP, C-IV, LN, TGF-β1)
Significant improvement (P < 0.05)
Less improvement
Key Findings
The combination therapy group had significantly greater reductions in systolic and diastolic blood pressure compared to monotherapy.
Glycemic control improved more markedly in the combination group, including fasting and postprandial glucose and glycemic variability indices.
Inflammatory and cardiac biomarkers (hs-CRP, TNF-α, IL-6, IL-33, sST2, sICAM-1) decreased significantly with combination therapy.
Echocardiographic parameters showed improved left ventricular ejection fraction in the combination group.
Renal function markers (eGFR, UACR, SCr, BUN) and fibrosis markers showed significant improvement with combination therapy.
Adding dapagliflozin to valsartan therapy in patients with T2DM and hypertension can provide enhanced cardiorenal protection beyond blood pressure and glycemic control alone. This combination addresses underlying inflammatory and fibrotic pathways, improving cardiac function and renal parameters. Clinicians should consider this combination to reduce the risk of cardiovascular and renal complications in this high-risk population.
Conclusion
The combination of dapagliflozin and valsartan offers superior cardiorenal benefits compared to valsartan monotherapy in patients with type 2 diabetes and hypertension, supporting its use as a multifaceted therapeutic strategy to improve clinical outcomes.
References
Study Authors/Institution 2024 -- Evaluating the Cardiorenal Benefits of Dapagliflozin and Valsartan in Individuals with Type 2 Diabetes and Hypertension
